What's new

Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,cilgavimab, Date of authorisation: 25/03/2022, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,cilgavimab, Date of authorisation: 25/03/2022, Revision: 9, Status: Authorised

Mar 12, 2025 - 16:56
 0
Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,cilgavimab, Date of authorisation: 25/03/2022, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,cilgavimab, Date of authorisation: 25/03/2022, Revision: 9, Status: Authorised
Read More

Tags:

Previous Article

IRIS guide for applicants - How to create and submit scientific applications, fo...

Next Article

UVM Health expands child care for employees

Related Posts

Summary of opinion: Ixchiq, 27/02/2025 Positive

Summary of opinion: Ixchiq, 27/02/2025 Positive

Feb 28, 2025  0

Minimum inhibitory concentration (MIC) breakpoints

Feb 21, 2025  0

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025  0